Drug intelligence / Profile preview

Pataday Extra Strength

Development stage
Unknown
Lead developer
Alcon
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

**Pataday Extra Strength** is an over-the-counter ophthalmic antihistamine product developed and manufactured by **Alcon Vision** for the temporary relief of allergic eye itch associated with allergic conjunctivitis. It contains **olopatadine hydrochloride 0.7%**, a **small-molecule** selective histamine receptor antagonist with mast cell-stabilizing anti-allergic activity, administered as a **once-daily ophthalmic solution**. The product is the highest-strength formulation in the Pataday line and was transitioned from the former prescription brand **Pazeo** to OTC status for 24-hour relief of ocular itching triggered by allergens such as pollen, ragweed, grass, animal hair, and dander.

Brand names
Pataday Extra StrengthPataday Once Daily Relief Extra Strength
Other names
olopatadine hydrochloride ophthalmic solution 0.7%Pazeo
02

Targets

Ca signaling (Calcium signaling family)HRH3 (Histamine Receptor H3)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)

Beyond the preview

Go deeper on Pataday Extra Strength.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pataday Extra Strength.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call